Cao Xuezhi, Fu Yang-Xin, Peng Hua
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, China.
Guangzhou National Laboratory, Bio-Island, Guangzhou 510005, China.
Vaccines (Basel). 2024 Apr 29;12(5):477. doi: 10.3390/vaccines12050477.
Tuberculosis, caused by (), remains a formidable global health challenge, affecting a substantial portion of the world's population. The current tuberculosis vaccine, bacille Calmette-Guérin (BCG), offers limited protection against pulmonary tuberculosis in adults, underscoring the critical need for innovative vaccination strategies. Cytokines are pivotal in modulating immune responses and have been explored as potential adjuvants to enhance vaccine efficacy. The strategic inclusion of cytokines as adjuvants in tuberculosis vaccines holds significant promise for augmenting vaccine-induced immune responses and strengthening protection against . This review delves into promising cytokines, such as Type I interferons (IFNs), Type II IFN, interleukins such as IL-2, IL-7, IL-15, IL-12, and IL-21, alongside the use of a granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant, which has shown effectiveness in boosting immune responses and enhancing vaccine efficacy in tuberculosis models.
由（）引起的结核病仍然是一项严峻的全球健康挑战，影响着世界上很大一部分人口。目前的结核病疫苗卡介苗（BCG）对成人肺结核的保护作用有限，这凸显了对创新疫苗接种策略的迫切需求。细胞因子在调节免疫反应中起着关键作用，并已被探索作为增强疫苗效力的潜在佐剂。在结核病疫苗中战略性地加入细胞因子作为佐剂，对于增强疫苗诱导的免疫反应和加强对（）的保护具有重大前景。本综述深入探讨了有前景的细胞因子，如I型干扰素（IFN）、II型干扰素、白细胞介素如IL-2、IL-7、IL-15、IL-12和IL-21，以及使用粒细胞巨噬细胞集落刺激因子（GM-CSF）作为佐剂，后者在结核病模型中已显示出在增强免疫反应和提高疫苗效力方面的有效性。
